This trial doesn't tell you that -- there are few participants that only received a single dose. Can tell.
The issue is the validity of the trial. It has significant deficiencies that make reading the results difficult -- confounding, statistical manipulations, small recurrent OS sample. Regulators will find it difficult to read results.
It looks like about 62 patients who took DcVaxL are still alive. LL said 25 from Phase 3, 25 from Info or Compassionate Arm and another 12 from some other category like pseudoprogressors treated separately. She said all those living are with no progression or tumor eliminated. All 62 might be living for more than 5 years. It means GBM cure! Al asked her what is the possibility DcVaxL goes for all solid tumors. LL went so beaming all over her face with a big smile with a nodding sign. Yes, tumor agnostic guidance is all for us.
Market Data 
Markets 
AI
